NUTM2F

Across TCGA pan-cancer cohorts, NUTM2F mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NUTM2F data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NUTM2F mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NUTM2F expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where NUTM2F mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.724	0.443	.021	19	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	10	view →
CCRCC	DFS	Median	II,III,IV	0.786	0.953	.036	6	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NUTM2F–LUAD (DFS)

Open the LUAD breakdown →